Evidence map›Paper›PMID 42612652›Full record

Trial reportThe Lancet. Microbe2026

Effects of attenuated influenza virus administration to young children on pneumococcal density and acquisition in UK families: a randomised controlled trial.

Jane Metz, George Qian, Begonia Morales-Aza, Jennifer Oliver, Elizabeth Oliver, Helen Rice, Kaltun Duale, Paul Heath, Saul Faust, Matthew Snape and 9 more

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in The Lancet. Microbe, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Jane MetzBristol Vaccine Centre, School of Cellular and Molecular Medicine and School of Population Health Sciences, University of Bristol, Bristol, UK; Bristol Royal Hospital for Children, University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK. Electronic address: jane.metz@bristol.ac.uk.
George QianBristol Vaccine Centre, School of Cellular and Molecular Medicine and School of Population Health Sciences, University of Bristol, Bristol, UK; Department of Engineering Mathematics, University of Bristol, Bristol, UK.
Begonia Morales-AzaBristol Vaccine Centre, School of Cellular and Molecular Medicine and School of Population Health Sciences, University of Bristol, Bristol, UK.
Jennifer OliverBristol Vaccine Centre, School of Cellular and Molecular Medicine and School of Population Health Sciences, University of Bristol, Bristol, UK.
Elizabeth OliverBristol Vaccine Centre, School of Cellular and Molecular Medicine and School of Population Health Sciences, University of Bristol, Bristol, UK.
Helen RiceBristol Vaccine Centre, School of Cellular and Molecular Medicine and School of Population Health Sciences, University of Bristol, Bristol, UK.
Kaltun DualeBristol Vaccine Centre, School of Cellular and Molecular Medicine and School of Population Health Sciences, University of Bristol, Bristol, UK.
Paul HeathVaccine Institute, Centre for Neonatal and Paediatric Infection, City St Georges, University of London, London, UK.
Saul FaustNIHR Southampton Clinical Research Facility, University of Southampton, Southampton, UK.
Matthew SnapeOxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
Stephen HughesManchester University NHS Foundation Trust, Department of Paediatric Allergy and Immunology, Royal Manchester Children's Hospital, Manchester, UK.
Laura HoleDepartment of Paediatrics, Gloucestershire Royal Hospital, Gloucester, UK.
Rebecca MannDepartment of Paediatrics, Musgrove Park Hospital, Taunton, UK.
Fiona ShackleyDepartment of Paediatrics, Sheffield Children's Hospital, Sheffield, UK.
Peter RuddDepartment of Paediatrics, Royal United Hospital Bath NHS Foundation Trust, Bath, UK.
Siân LudmanDepartment of Paediatrics, Royal Devon and Exeter NHS Foundation Trust, Exeter, UK.
Bradford GessnerPfizer Vaccines, Collegeville, PA, USA.
Leon DanonBristol Vaccine Centre, School of Cellular and Molecular Medicine and School of Population Health Sciences, University of Bristol, Bristol, UK; Department of Engineering Mathematics, University of Bristol, Bristol, UK.
Adam FinnBristol Vaccine Centre, School of Cellular and Molecular Medicine and School of Population Health Sciences, University of Bristol, Bristol, UK; Bristol Royal Hospital for Children, University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe live attenuated influenza vaccine (LAIV) is offered in the UK to young children, protecting against influenza for those vaccinated, and as an indirect protection for the wider community. LAIV has also been shown to increase carriage density of Streptococcus pneumoniae, to an extent, in children. This study sought to confirm whether the vaccine, as a viral proxy, leads to an increase in carriage density in children and, if so, whether this increase augments S pneumoniae acquisition in household contacts.

methodsWe conducted a randomised control study (ISRCTN10720581, now complete) across ten UK sites. We included families having a child aged 2 years (index child) and due to receive their first LAIV dose under National Health Service criteria, and at least two other household contacts. Participants were excluded when the index child was ineligible for LAIV, had primary or secondary immunodeficiency, or was currently enrolled in other trials or circumstances that could jeopardise participation or data integrity during the study. Families were randomly assigned (1:1) to either the early LAIV group or late LAIV group using a single central allocation service with computerised randomisation for all sites. After randomisation, families and clinical research staff were unmasked; however, laboratory and analytical research staff remained masked. Nasopharyngeal swabs were collected from all participants over five visits, each 2 weeks apart, and tested for pneumococcal carriage by quantitative PCR for lytA, with a cycle threshold (Ct) cutoff of 35, and Ct values converted to gene copies per mL. LAIV was given to index children at visit 1 in the early LAIV group and at visit 3 in the late LAIV group. The coprimary outcomes of this study were S pneumoniae density in index children at 14 and 28 days after LAIV as compared with that on day 0, and the prevalence, at days 14 and 28, of S pneumoniae colonisation in the household contacts of index children who were S pneumoniae-positive at baseline. We developed regression models to analyse the association between vaccination and whether an increase in pneumococcal density was observed 14 and 28 days later, in addition to an increase in the odds of S pneumoniae acquisition in household members after administering LAIV. Serious adverse events were recorded if reported to the study team and were assessed by the Chief Investigator for seriousness, expectedness, and relatedness to LAIV or study procedures.

findings405 families were enrolled between Oct 3, and Oct 30, 2017, and between Sept 27, and Nov 2, 2018. 205 families (703 participants) were allocated to the early LAIV group and 200 (676 participants) to the late LAIV group. Data on sex were available for 402 of 405 index participants. In the early LAIV group, 116 (58%) of 202 index children were female and 86 (42%) were male, and the median age was 2·47 years (IQR 0·331); in the late LAIV group, 91 (46%) of 200 index children were female and 108 (54%) were male, and the median age was 2·47 years (0·333). In the early LAIV group, 276 (59%) of 470 household contacts were female and 194 (41%) were male, and the median age of contacts was 33·8 (IQR 31·7); in the late LAIV group 272 (60%) of 453 household contacts were female and 181 (40%) were male, and the median age of contacts was 33·1 (IQR 31·4). 388 (96%) of 405 households, including 1309 (95%) of the 1379 participants, completed the study. Regression analyses showed that there was a 2·5-times (95% CI 1·5-4·3, p=0·0008) increase in the odds of vaccinated children having increased pneumococcal density 14 days later, compared with that in unvaccinated children, and a 2·0-times (95% CI 1·2-3·5, p=0·015) increase in the odds of household contacts S pneumoniae acquisition. These effects appear to have attenuated by day 28, on which there was a 1·5 times (95% CI 0·88-2·5, p=0·14) increase in odds of vaccinated children having increased pneumococcal density compared with that in unvaccinated children and a 0·89 times (95% CI 0·53-1·5, p=0·67) the odds of household contacts S pneumoniae acquisition. Three serious adverse events related to pregnancy and breastfeeding were reported, which were deemed to be unrelated to the study.

interpretationOur results show that in young children colonised with S pneumoniae, infection with an attenuated influenza virus in the 2 weeks after vaccination increases the risk of pneumococcal acquisition among their close contacts. This effect appears to be driven by a vaccine-induced rise in bacterial density. On the basis of our results, density of bacterial nasal colonisation in young children could be used to model transmission dynamics, both at the individual and population levels.

fundingUniversity of Bristol, Gates Foundation, Pfizer, European Society of Paediatric Infectious Diseases.

Indexed as

Carrier StateInfluenza, HumanInfluenza VaccinesPneumococcal InfectionsStreptococcus pneumoniaeChild, PreschoolFemaleHumansInfantMaleNasopharynxUnited KingdomVaccines, AttenuatedInfluenza VaccinesVaccines, Attenuated

Identifiers

PMID42612652
PMCPMC13633236

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.